Bingham McCutchen LLP has hired four partners from intellectual property boutique Burns, Doane, Swecker & Mathis LLP, including managing partner Danny Huntington.
The U.S. Court of Appeals for the Federal Circuit has denied Merck’s petition for an en-banc rehearing of a panel’s decision that invalidated one of the patents for its best-selling osteoporosis treatment Fosamax.
Dykema Gossett PLLC has hired former Brinks Hofer Gilson & Lione partner Allan J. Sternstein to take the helm of the firm’s intellectual property litigation team.
European generic drug makers have launched a campaign to amend European Union plans to offer six months of extended marketing exclusivity for drugs that undergo pediatric testing.
In a case with broad implications for the pharmaceutical industry, the U.S. Supreme Court appeared skeptical Wednesday of an appeal court’s narrow interpretation of a statute that shields drug companies from patent liability in their research and development.
Duane Morris LLP has hired Bradford J. Duft to its San Diego office, the fourth attorney the firm has poached from Buchanan Ingersoll PC.
A federal judge has dismissed Tercica, Inc.’s and Genentech, Inc.’s patent infringement lawsuit against rival Insmed Inc. over its SomatoKine growth hormone treatment.
Generic drug makers Dr. Reddy's Laboratories and Ivax have vowed to appeal last week's ruling by an Indiana federal court that upheld Eli Lilly's patent on the blockbuster schizophrenia drug Zyprexa.
A landmark patent case before the U.S. Supreme Court this week could have broad implications for research exemptions to patent infringement liability.
A Delaware federal court has postponed the trial in Impax Laboratories, Inc.’s patent challenge against Shire Pharmaceuticals Group’s best-selling attention-deficit-disorder treatment Adderall XR until February 2006.
A California federal court has ruled that the design of a Medtronic Inc. spinal implant polyaxial screw infringes a patent held by musculoskeletal products company Biomet Inc.
The U.S. Food and Drug Administration has granted Barr Laboratories a final approval for a generic version of Aventis Pharmaceuticals' blockbuster allergy medicine Allegra-D, the company said.
In a major victory for Eli Lilly & Co., an Indiana federal judge has upheld the patent on the key ingredient on its $4.4 billion-a-year Zyprexa schizophrenia drug.
An Indiana judge will render his decision Thursday afternoon in Eli Lilly & Co.’s closely watched patent infringement lawsuit against would-be makers of generic versions of the company’s blockbuster schizophrenia treatment Zyprexa.
Barr Pharmaceuticals Inc. and Kos Pharmaceuticals Inc. have penned an unusual settlement agreement to put an end to their patent litigation over Kos' cholesterol lowering drugs Niaspan and Advicor, the two companies said Wednesday.
Shire Pharmaceuticals Group has decided not to sue Israeli generics maker Teva Pharmaceuticals USA Inc. over its application for a generic version of the best-selling attention deficit drug Adderall XR.
Generic drug maker Barr Pharmaceuticals Inc. has dropped a lawsuit against the U.S. Food and Drug Administration over exclusive marketing rights to a generic version of Sanofi-Aventis’ allergy treatment Allegra.
In an attempt to crack down on fast-growing cross-border sales of prescription drugs to U.S. consumers, drug maker Merck & Co. has filed a series of lawsuits against Canadian online pharmacies that ship Apotex’ generic version of Zocor south of the border.
The U.S. Court of Appeals for the Federal Circuit has dismissed Canadian generics maker Apotex Inc.’s lawsuit against Pfizer, Inc. after Pfizer covenanted not to sue Apotex for infringement of a patent for the hypertension drug Accupril.
The U.S. Court of Appeals for the Federal Circuit has revived a lawsuit filed by Tyco International Ltd.'s Nellcor unit against Masimo Corp. over a patent for machines that measure the oxygen content in blood.